Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Antibody titers before and after booster doses of SARS-CoV-2 mRNA vaccines in healthy adults

Alexis R. Demonbreun, Amelia Sancilio, Lauren A. Vaught, Nina L. Reiser, Lorenzo Pesce, Elizabeth M. McNally, Thomas W. McDade
doi: https://doi.org/10.1101/2021.11.19.21266555
Alexis R. Demonbreun
1Center for Genetic Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: t-mcdade{at}northwestern.edu alexis.demonbreun{at}northwestern.edu
Amelia Sancilio
2Department of Anthropology and Institute for Policy Research, Northwestern University, Evanston, IL
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauren A. Vaught
1Center for Genetic Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
BS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nina L. Reiser
1Center for Genetic Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
BS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lorenzo Pesce
2Department of Anthropology and Institute for Policy Research, Northwestern University, Evanston, IL
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth M. McNally
1Center for Genetic Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
MD PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas W. McDade
2Department of Anthropology and Institute for Policy Research, Northwestern University, Evanston, IL
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: t-mcdade{at}northwestern.edu alexis.demonbreun{at}northwestern.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Two-dose messenger RNA vaccines (BNT162b2/Pfizer and mRNA-1273/Moderna) against SARS-CoV-2 were rolled out in the US in December 2020, and provide protection against hospitalization and death from COVID-19 for at least six months. Breakthrough infections have increased with waning immunity and the spread of the B.1.617.2 (Delta) variant in summer 2021, prompting approval of boosters for all adults over 18. We measured anti-receptor binding domain (RBD) IgG and surrogate virus neutralization of the interaction between SARS-CoV-2 spike protein and the human angiotensin-converting enzyme (ACE2) receptor, before and after boosters in N=33 healthy adults. We document large antibody responses 6-10 days after booster, with antibody levels that exceed levels documented after natural infection with COVID-19, after two doses of vaccine, or after both natural infection and vaccination. Surrogate neutralization of B.1.617.2 is high but reduced in comparison with wild-type SARS-CoV-2. These data support the use of boosters to prevent breakthrough infections and suggest that antibody-mediated immunity may last longer than after the second vaccine dose.

Competing Interest Statement

Thomas McDade has a financial interest in EnMed Microanalytics, a company that specializes in laboratory testing of dried blood spot samples. All other authors declare no conflicts of interest.

Funding Statement

Supported by the National Science Foundation 2035114, NIH 3UL1TR001422-06S4, Northwestern University Office of Research, and a generous gift from Dr. Andrew Senyei and Noni Senyei. The funding sources had no role in the study design, data collection, analysis, interpretation, or writing of the report.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All research activities were implemented under protocols approved by the institutional review board at Northwestern University (#STU00212457 and #STU00212472).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Requests for the potentially identifiable dataset should be made by qualified researchers trained in human subject confidentiality protocols to Dr. Thomas McDade at Northwestern University.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted November 21, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Antibody titers before and after booster doses of SARS-CoV-2 mRNA vaccines in healthy adults
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Antibody titers before and after booster doses of SARS-CoV-2 mRNA vaccines in healthy adults
Alexis R. Demonbreun, Amelia Sancilio, Lauren A. Vaught, Nina L. Reiser, Lorenzo Pesce, Elizabeth M. McNally, Thomas W. McDade
medRxiv 2021.11.19.21266555; doi: https://doi.org/10.1101/2021.11.19.21266555
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Antibody titers before and after booster doses of SARS-CoV-2 mRNA vaccines in healthy adults
Alexis R. Demonbreun, Amelia Sancilio, Lauren A. Vaught, Nina L. Reiser, Lorenzo Pesce, Elizabeth M. McNally, Thomas W. McDade
medRxiv 2021.11.19.21266555; doi: https://doi.org/10.1101/2021.11.19.21266555

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (756)
  • Anesthesia (221)
  • Cardiovascular Medicine (3294)
  • Dentistry and Oral Medicine (364)
  • Dermatology (279)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1171)
  • Epidemiology (13376)
  • Forensic Medicine (19)
  • Gastroenterology (899)
  • Genetic and Genomic Medicine (5153)
  • Geriatric Medicine (482)
  • Health Economics (783)
  • Health Informatics (3268)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1190)
  • Hematology (431)
  • HIV/AIDS (1017)
  • Infectious Diseases (except HIV/AIDS) (14629)
  • Intensive Care and Critical Care Medicine (913)
  • Medical Education (477)
  • Medical Ethics (127)
  • Nephrology (523)
  • Neurology (4925)
  • Nursing (262)
  • Nutrition (730)
  • Obstetrics and Gynecology (883)
  • Occupational and Environmental Health (795)
  • Oncology (2524)
  • Ophthalmology (724)
  • Orthopedics (281)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (543)
  • Pediatrics (1302)
  • Pharmacology and Therapeutics (550)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4212)
  • Public and Global Health (7504)
  • Radiology and Imaging (1706)
  • Rehabilitation Medicine and Physical Therapy (1013)
  • Respiratory Medicine (980)
  • Rheumatology (480)
  • Sexual and Reproductive Health (497)
  • Sports Medicine (424)
  • Surgery (548)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (205)